Kyoto University team develops pain reliever comparable to morphine
Morphine, often administered to cancer patients, has serious adverse effects such as breathing issues and addiction.
According to the team, the newly developed drug, Adriana, is a groundbreaking painkiller, which works on a completely different mechanism to morphine and other existing synthetic opioids. The drug has the potential to revolutionize pain control in the medical field, the team said.
The team also expects that the drug will help resolve the so-called opioid epidemic, in which a large number of deaths occur mainly due to overdoses of opioids.
Its findings were published in the online edition of the U.S. journal Proceedings of the National Academy of Sciences.
When a person encounters a life-threatening situation, norepinephrine, an organic chemical secreted from the brain, suppresses pain.
For its study, the team focused on the human body regulating oversecretion of norepinephrine. By introducing a new research technology, the team succeeded in developing a drug blocking such a control function for the first time in the world.
In a clinical trial conducted at the Kyoto University Hospital between January 2023 and December 2024, the team confirmed the new drug's efficiency to a certain extent for patients including 20 who underwent lung cancer surgery.
The team plans to conduct a clinical trial in the United States for 400 postsurgery patients in 2026, aiming to put Adriana into practical use in 2028.
"We hope that the new drug will help cancer patients who previously had no choice but to use opioids live their lives without pain as well as a need to worry about addiction or serious side effects," Masatoshi Hagiwara, a professor at the university, said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NHK
5 hours ago
- NHK
African forest elephant gives birth at Japanese zoo
An African forest elephant has given birth at a zoo in the Japanese city of Hiroshima. This is the first time an elephant of this endangered species has been born in Japan. Officials at Asa Zoological Park say the elephant, called May, gave birth to a baby shortly before 5 a.m. on Tuesday. The officials say the calf was smaller than expected, measuring about 75 centimeters at the highest point on its back. They add its gender is not yet known. The baby elephant was seen walking and trying to suckle. But it could not reach its mother's breast, so zookeepers have piled up straw on the floor to help it. The mother was also seen caring for the baby, touching it with her trunk. African forest elephants inhabit forest areas in Africa and have oval-shaped ears. There are only two in Japan -- May, a female, and Dai, a male. Both live in Asa Zoo. The zoo has been working to breed the pair. Last summer, it confirmed May's pregnancy, the first of this species in Japan. A woman in her 60s from Hiroshima said she is very happy about the birth and looks forward to seeing May and her baby playing together. Zoo director Abe Katsuhiko said he is relieved that the mother and baby are in good health. He added the zoo will closely monitor the baby's growth and ensure it does not get injured. The zoo says it will decide when visitors will be allowed to see the elephants by taking into account factors such as their health condition.
Japan Times
8 hours ago
- Japan Times
Drugmaker in Japan seeks approval for stem cell treatment for Parkinson's
Sumitomo Pharma said Tuesday it is seeking approval for a Parkinson's disease treatment that transplants stem cells into a patient's brain, following a successful clinical trial. The drugmaker applied to Japanese regulators for manufacturing and marketing authorization aimed at treating patients with advanced Parkinson's disease, it said in a statement. A trial led by Kyoto University researchers indicated that the company's treatment using induced Pluripotent Stem (iPS) cells — which have the potential to develop into any cell in the body — was safe and successful in improving symptoms. The study involved seven Parkinson's patients between 50 and 69 years old, with each receiving a total of either 5 million or 10 million cells implanted on both sides of the brain. The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease. The patients were monitored for two years, and no major adverse effects were found, the study said. Four patients showed improvements in symptoms, it said. The trial results were published in Nature in April. Sumitomo Pharma is also carrying out a clinical trial in the United States. Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement. Worldwide, about 10 million people have the illness, according to the Parkinson's Disease Foundation. Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation said. iPS cells are created by stimulating mature, already specialized, cells back into a juvenile state — basically cloning without the need for an embryo. The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.
Japan Times
14 hours ago
- Japan Times
Kyoto University team develops pain reliever comparable to morphine
A Kyoto University research team has developed a pain-reliever that is comparable to morphine but does not have serious side effects. Morphine, often administered to cancer patients, has serious adverse effects such as breathing issues and addiction. According to the team, the newly developed drug, Adriana, is a groundbreaking painkiller, which works on a completely different mechanism to morphine and other existing synthetic opioids. The drug has the potential to revolutionize pain control in the medical field, the team said. The team also expects that the drug will help resolve the so-called opioid epidemic, in which a large number of deaths occur mainly due to overdoses of opioids. Its findings were published in the online edition of the U.S. journal Proceedings of the National Academy of Sciences. When a person encounters a life-threatening situation, norepinephrine, an organic chemical secreted from the brain, suppresses pain. For its study, the team focused on the human body regulating oversecretion of norepinephrine. By introducing a new research technology, the team succeeded in developing a drug blocking such a control function for the first time in the world. In a clinical trial conducted at the Kyoto University Hospital between January 2023 and December 2024, the team confirmed the new drug's efficiency to a certain extent for patients including 20 who underwent lung cancer surgery. The team plans to conduct a clinical trial in the United States for 400 postsurgery patients in 2026, aiming to put Adriana into practical use in 2028. "We hope that the new drug will help cancer patients who previously had no choice but to use opioids live their lives without pain as well as a need to worry about addiction or serious side effects," Masatoshi Hagiwara, a professor at the university, said.
